News

Advancing a regenerative program for type 1 diabetes.

Company announcements and selected press coverage of Elvinix.

Announcements

Licensing AgreementSeptember 15, 2026

Elvinix secures an exclusive license from Zealand Pharma to advance a GLP-1/gastrin dual-agonist peptide therapy for type 1 diabetes.

Read the announcement